Biogen Inc. is slated to report its third-quarter earnings on Tuesday amid cautious hope for its neurodegenerative disease programs, including Alzheimer's, and an ongoing CEO search.
The Cambridge drugmaker (Nasdaq: BIIB) has suffered a series of setbacks over the last year, driven in large part by the commercial failure of its controversial Alzheimer's disease drug, Aduhelm. Without any real revenue from sales of the new drug, Biogen faces headwinds from new generics and biosimilars that threaten…
